Granted Patent
B2
US 12,214,036 · App. 17/193,631 · Granted Feb 4, 2025
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
Assignee:
Incyte Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.
Claims (27)
1. A method of treating cancer in a patient, comprising administering to said patient:
(i) Compound 1, having the structure:
or a pharmaceutically acceptable salt thereof; and
(ii) an antibody, or an antigen-binding fragment thereof, that binds to human PD-1, wherein the antibody, or the antigen-binding fragment thereof comprises a variable heavy (VH) domain and a variable light (VL) domain, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:4 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:5;
wherein the cancer is colorectal cancer.
2. The method of claim 1 , wherein Compound 1 and the antibody are administered simultaneously.
3. The method of claim 1 , wherein Compound 1 and the antibody are administered sequentially.
4. The method of claim 1 , wherein Compound 1 is administered orally.
5. The method of claim 1 , wherein the antibody or antigen-binding fragment is administered via intravenous administration.
6. The method of claim 1 , wherein the antibody or antigen-binding fragment is administered at a dose of 375 mg once every 3 weeks.
7. The method of claim 1 , wherein the antibody or antigen-binding fragment is administered at a dose of 500 mg once every 4 weeks.
8. The method of claim 1 , wherein the antibody or antigen-binding fragment is administered at a dose of 750 mg once every 4 weeks.
9. The method of claim 1 , wherein:
(a) the antibody comprises an Fc Region and a Hinge Domain;
(b) the Fc Region and the Hinge Domain are of the IgG4 type; and
(c) the Hinge Domain comprises a stabilizing mutation.
10. The method of claim 1 , wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2.
11. The method of claim 1 , wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.
12. The method of claim 1 , wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 2 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.
13. The method of claim 1 , wherein the antibody comprises an Fc Region that is of the IgG1 type.
14. The method of claim 1 , wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:13.
15. The method of claim 1 , wherein the antibody comprises a light chain and a heavy chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 13 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.
16. The method of claim 1 , wherein the antibody is a humanized antibody.
17. The method of claim 1 , wherein:
a) Compound 1 and the antibody are administered sequentially;
b) Compound 1 is administered orally; and
c) the antibody or antigen-binding fragment is administered via intravenous administration.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 16, 2021
From: RIOS-DORIA, JONATHAN; KOBLISH, HOLLY K.
To: INCYTE CORPORATION
Reel/Frame 056561/0270 →
Continuity (2)
Provisional Application
62986482
· Mar 6, 2020
References Cited (400)
US 4399216A
· Axel et al.
· 1983
[cited by applicant]
US 4634665A
· Axel et al.
· 1987
[cited by applicant]
US 5057313A
· Shih et al.
· 1991
[cited by applicant]
US 5156840A
· Goers et al.
· 1992
[cited by applicant]
US 5179017A
· Axel et al.
· 1993
[cited by applicant]
US 5530101A
· Queen et al.
· 1996
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5693761A
· Queen et al.
· 1997
[cited by applicant]
US 5693762A
· Queen et al.
· 1997
[cited by applicant]
US 5714350A
· Co et al.
· 1998
[cited by applicant]
US 5731168A
· Carter et al.
· 1998
[cited by applicant]
US 5849992A
· Meade et al.
· 1998
[cited by applicant]
US 5859205A
· Adair et al.
· 1999
[cited by applicant]
US 5869046A
· Presta et al.
· 1999
[cited by applicant]
US 6300064B1
· Knappik et al.
· 2001
[cited by applicant]
US 6350861B1
· Co et al.
· 2002
[cited by applicant]
US 6407213B1
· Carter et al.
· 2002
[cited by applicant]
US 8791257B2
· Markwalder et al.
· 2014
[cited by applicant]
US 9708333B2
· Li et al.
· 2017
[cited by applicant]
US 9840503B2
· Sun et al.
· 2017
[cited by applicant]
US 9981975B2
· Li
· 2018
[cited by examiner]
US 20050008625A1
· Balint et al.
· 2005
[cited by applicant]
US 20050079574A1
· Bond
· 2005
[cited by applicant]
US 20220022770A1
· Jia
· 2022
[cited by examiner]
CL 2018002759
· 2018
[cited by applicant]
CL 2018000949
· 2018
[cited by applicant]
CL 2019000043
· 2019
[cited by applicant]
CL 2019000115
· 2019
[cited by applicant]
CN 101084218
· 2007
[cited by applicant]
CN 102408411
· 2012
[cited by applicant]
CN 102918045
· 2013
[cited by applicant]
CN 101641093
· 2013
[cited by applicant]
CN 103124729
· 2013
[cited by applicant]
CN 103608342
· 2014
[cited by applicant]
CN 102482278
· 2015
[cited by applicant]
CN 105732634
· 2016
[cited by applicant]
CO 20210000923
· 2021
[cited by applicant]
EP 0404097
· 1990
[cited by applicant]
EP 2320902
· 2011
[cited by applicant]
EP 2465505
· 2012
[cited by applicant]
EP 2484679
· 2012
[cited by applicant]
EP 2552922
· 2013
[cited by applicant]
EP 2810937
· 2014
[cited by applicant]
EP 2791140
· 2016
[cited by applicant]
ES 2253774
· 2006
[cited by applicant]
ES 2307003
· 2008
[cited by applicant]
ES 2351612
· 2011
[cited by applicant]
IN 201817040446
· 2019
[cited by applicant]
JP H0395163
· 1991
[cited by applicant]
JP 2008501703
· 2008
[cited by applicant]
JP 2009518303
· 2009
[cited by applicant]
JP 2009519222
· 2009
[cited by applicant]
JP 2009519905
· 2009
[cited by applicant]
JP 2010522742
· 2010
[cited by applicant]
JP 2010529196
· 2010
[cited by applicant]
JP 2012525400
· 2012
[cited by applicant]
JP 2014525902
· 2014
[cited by applicant]
JP 2015532287
· 2015
[cited by applicant]
JP 2019510043
· 2019
[cited by applicant]
JP 2021529765
· 2021
[cited by applicant]
KR 20130141706
· 2013
[cited by applicant]
KR 20150061651
· 2015
[cited by applicant]
WO WO199007861
· 1990
[cited by applicant]
WO WO199311161
· 1993
[cited by applicant]
WO WO2001019828
· 2001
[cited by applicant]
WO WO2002000196
· 2002
[cited by applicant]
WO WO2002080975
· 2002
[cited by applicant]
WO WO2004026840
· 2004
[cited by applicant]
WO WO2004035580
· 2004
[cited by applicant]
WO WO2005003175
· 2005
[cited by applicant]
WO WO2005018572
· 2005
[cited by applicant]
WO WO2005025515
· 2005
[cited by applicant]
WO WO2006046023
· 2006
[cited by applicant]
WO WO2006056399
· 2006
[cited by applicant]
WO WO2007061737
· 2007
[cited by applicant]
WO WO2007064883
· 2007
[cited by applicant]
WO WO2007070514
· 2007
[cited by applicant]
WO WO2007120752
· 2007
[cited by applicant]
WO WO2007125315
· 2007
[cited by applicant]
WO WO2008048375
· 2008
[cited by applicant]
WO WO2008076392
· 2008
[cited by applicant]
WO WO2018198077
· 2008
[cited by applicant]
WO WO2009022354
· 2009
[cited by applicant]
WO WO2009023269
· 2009
[cited by applicant]
WO WO2009047514
· 2009
[cited by applicant]
WO WO2009053737
· 2009
[cited by applicant]
WO WO2009054864
· 2009
[cited by applicant]
WO WO2009085185
· 2009
[cited by applicant]
WO WO2009087225
· 2009
[cited by applicant]
WO WO2009127417
· 2009
[cited by applicant]
WO WO2009134723
· 2009
[cited by applicant]
WO WO2010005876
· 2010
[cited by applicant]
WO WO2010005879
· 2010
[cited by applicant]
WO WO2010008454
· 2010
[cited by applicant]
WO WO2010014755
· 2010
[cited by applicant]
WO WO2010025073
· 2010
[cited by applicant]
WO WO2010071885
· 2010
[cited by applicant]
WO WO2010090764
· 2010
[cited by applicant]
WO WO2011038185
· 2011
[cited by applicant]
WO WO2011045084
· 2011
[cited by applicant]
WO WO2011139273
· 2011
[cited by applicant]
WO WO2011146313
· 2011
[cited by applicant]
WO WO2012028332
· 2012
[cited by applicant]
WO WO2012048129
· 2012
[cited by applicant]
WO WO2012129344
· 2012
[cited by applicant]
WO WO2012135800
· 2012
[cited by applicant]
WO WO2012174082
· 2012
[cited by applicant]
WO WO2013040286
· 2013
[cited by applicant]
WO WO2013052417
· 2013
[cited by applicant]
WO WO2013074633
· 2013
[cited by applicant]
WO WO2013085802
· 2013
[cited by applicant]
WO WO2013115280
· 2013
[cited by applicant]
WO WO2013162061
· 2013
[cited by applicant]
WO WO2014062774
· 2014
[cited by applicant]
WO WO2014079545
· 2014
[cited by applicant]
WO WO2014109858
· 2014
[cited by applicant]
WO WO2014164729
· 2014
[cited by applicant]
WO WO2015012298
· 2015
[cited by applicant]
WO WO2015068767
· 2015
[cited by applicant]
WO WO2015081783
· 2015
[cited by applicant]
WO WO2015132799
· 2015
[cited by applicant]
WO WO2016097918
· 2016
[cited by applicant]
WO WO2016183071
· 2016
[cited by applicant]
WO WO2017027717
· 2017
[cited by applicant]
WO WO2017019846A1
· 2017
[cited by examiner]
WO WO2017062797
· 2017
[cited by applicant]
WO WO2017083788
· 2017
[cited by applicant]
WO WO2017083789
· 2017
[cited by applicant]
WO WO2017172596
· 2017
[cited by applicant]
WO WO2017184934
· 2017
[cited by applicant]
WO WO2019067594
· 2019
[cited by applicant]
Optum, Inc., “The New Age of Oncology Drugs”; URL = https://www.optum.com/business/insights/state-government/page.hub.oncology-drug-advances.html; Accessed Jun. 21, 2023; (C) 2023 by Optum, Inc. (Year: 2023).
[cited by examiner]
Affouard et al., “Multi-Kilo Delivery of AMG 925 Featuring a Buchwald-Hartwig Amination and Processing with Insoluble Synthetic Intermediates,” Organic Process Research & Development, 2015, 19: 476-485.
[cited by applicant]
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol. Immunol., 1993, 30:105-108.
[cited by applicant]
Angelillo-Scherrer et al., “Role of Gas6 in erythropoiesis and anemia in mice,” J. Clin. Invest., 2008, 118: 583-596.
[cited by applicant]
Anonymous: “Study Record Versions History of Changes for Study: NCT03522142 a Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies,” Mar. 20, 2020[retrieved on Jun. 4, 202…
[cited by applicant]
Ash and Ash, “Handbook of Pharmaceutical Additives,” Gower Publishing Company, 2007, 3rd Edition, 1 page, Title Page.
[cited by applicant]
Australian Office Action in Australian Application No. 2017241524, Jun. 26, 2020, 4 pages.
[cited by applicant]
Avilla et al., “Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer,” Cancer Res., Mar. 1, 2011, 71(5):1792-1804.
[cited by applicant]
Badaway et al., “Salt Selection for Pharmaceutical Compounds,” Preformulation in Solid Dosage Form Development(Informa Healthcare), 2008, Chapter 2.3, 63-80.
[cited by applicant]
Baladi et al., “State-of-the-art of small molecule inhibitors of the TAM family: The point of view of the chemist,” European Journal of Medicinal Chemistry, Oct. 2015, 105: 220-237.
[cited by applicant]
Balupuri et al., “Molecular modeling study on Mer kinase inhibitors using 3D-QSAR and docking approaches,” Medicinal Chemistry Research, Jul. 2015, 24(10): 3730-3742.
[cited by applicant]
Bastin et al., “Salt Selection and Optimization Procedures for Pharmaceutical New Chemicalls Entities,” Organic Process Research & Development, 2000, 4(5):427-435.
[cited by applicant]
Ben-Batalla et al., “Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia,” Clinical Cancer Research, May 1, 2017, 23(9):2289-2300.
[cited by applicant]
Ben-Batalla., “Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma,” Blood, Oct. 3, 2013, 122(14):2443-2452.
[cited by applicant]
Berge, “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 1997, 66(1):1-19.
[cited by applicant]
Berraondo et al., “Cytokines in clinical cancer immunotherapy,” British Journal of Cancer, 2019, 120:6-15.
[cited by applicant]
Better et al., “
[cited by applicant]
Better, “Expression of engineered antibodies and antibody fragments in microorganisms,” Methods in Enzymology, 1989, 178:476-496.
[cited by applicant]
Bird et al., “Single chain antibody variable regions,” Trends Biotechnol., Apr. 1991, 9:132-137.
[cited by applicant]
Blom et al., “Optimizing Preparative LC/MS Configurations and Methods for Parallel Synthesis Purification,” J. Comb. Chem., 2003, 5: 670-683.
[cited by applicant]
Blom et al., “Preparative LC-MS Purification: Improved Compound-Specific Method Optimization,” J. Comb. Chem., 2004, 6: 874-883.
[cited by applicant]
Blom, “Two-Pump at-Column-Dilution Configuration for Preparative Liquid Chromatography-Mass Spectrometry,” J. Comb. Chem., 2002, 4: 295-301.
[cited by applicant]
Borovik et al., “Pyrimidines. XLIX. Synthesis of 9-phenylpyrimido[4,5-b] indoles,” Izvestiya Sibirskogo Otdeleniya Akademii Nauk SSSR, Seriya Khimicheskikh Nauk , 1975, 137-41 (English abstract only).
[cited by applicant]
Borovik et al., “Synthesis of 2-substituted pyrimido[4,5-b]indoles and N-phenyl-2,2-diethoxy-3-arylideneindolines,” v sb., Khimiya i Farmakol. Indol'n. Soedinenii, 1975, 50 (English abstract only).
[cited by applicant]
Boyd, “Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen,” Drug Development Research, Feb. 1995, 34(2):91-109.
[cited by applicant]
Brazilian Office Action in Brazilian Application No. BR112020006145-0, dated Sep. 9, 2022, 7 pages.
[cited by applicant]
Brunton et al., “Chemotherapy of Neoplastic Diseases,” Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 2008, pp. 853-908.
[cited by applicant]
Burbridge et al., “S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab,” AACR Journals, 2013, 1749-1762.
[cited by applicant]
Carter et al., “High level
[cited by applicant]
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” PNAS, 1992, 89: 4285-4289.
[cited by applicant]
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
[cited by applicant]
Chambers et al., “Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells,” Immunity, Dec. 1997, 7(6): 885-95.
[cited by applicant]
Chilean Office Action in Chilean Application No., 202003397, dated Jun. 13, 2022, 14 pages.
[cited by applicant]
Chilean Office Action in Chilean Application No. 202000791, dated Jul. 15, 2021, 34 pages.
[cited by applicant]
Chinese Office Action in Chinese Application No. 201780031476.3, dated Oct. 28, 2020, 16 pages.
[cited by applicant]
Chinese Office Action in Chinese Application No. 201980055116.6, dated Jun. 22, 2022, 12 pages.
[cited by applicant]
Chothia et al., “Structural repertoire of the human VH segments,” J Mol Bio., 1992, 227:799-817.
[cited by applicant]
Chow et al., “Engineered of Pharmaceutical Materials: an Industrial Perspective,” J Pharmaceutical Sciences., Aug. 2008, 97(8):2855-2877.
[cited by applicant]
Chung et al., “Synthesis of certain [6:5:6] linear tricyclic nucleosides as potential antitumor agents,” Journal of Medicinal Chemistry, Nov. 1980, 23(11): 1158-66.
[cited by applicant]
Co et al., “A humanized antibody specific for the platelet integrin gpIIb/IIIa,” J Immunol., Mar. 15, 1994, 152(6):2968-2976 (Abstract Only).
[cited by applicant]
Cohen., “The development and therapeutic potential of protein kinase inhibitors,” Current Opinion in Chemical Biology, 1999, 3: 459-465, 1999.
[cited by applicant]
Colombian Office Action in Colombian Application No. NC2018/0011550, dated May 29, 2020, 16 pages.
[cited by applicant]
Colombian Office Action in Colombian Application No. NC2020/0005009, dated May 27, 2022, 22 pages.
[cited by applicant]
Colombian Office Action in Colombian Application No. NC2021/0004423, Aug. 2, 2021, 20 pages.
[cited by applicant]
Cook et al., “MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis,” J. Clin. Invest., Aug. 2013, 123(8): 3231-42.
[cited by applicant]
Cook et al., “The human immunoglobulin VH repertoire,” Immunol Today., 1995, 16: 237-242.
[cited by applicant]
Cosemans et al., “Potentiating role of Gas6 and Tryo3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization,” J. of Thrombosis and Haemostasis, 2010, 8: 1797-1808.
[cited by applicant]
Costa Rican Office Action in Costa Rican Application No. 2018-0516, dated May 4, 2022, 12 pages.
[cited by applicant]
Cruz-Cabeza et al., “Facts and Fictions about Polymorphism,” Chemical Society Reviews, 2015, 44:8619-8635.
[cited by applicant]
Datta et al., “Crystal Structures of Drugs: Advances in Determination, Prediction and engineering,” Nature, Jan. 2004, 3:42-57.
[cited by applicant]
Davies et al., “Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability,” Protein Eng., 1996, 9(6):531-537.
[cited by applicant]
Demarest et al., “Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines,” Biochemistry, May 2013, 52(18): 3102-18.
[cited by applicant]
Dermer et al., “Another Anniversary for the War on Cancer,” Bio/Technology, Mar. 1994, 12: 320.
[cited by applicant]
Devi et al, “Poloxamer: A Novel Functional Molecule for Drug Delivery and Gene Therapy,” J. Pharm. Sci. & Res., 2013, 5(8): 159-165.
[cited by applicant]
Divine et al., “AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer,” Oncotarget, Nov. 22, 2016, 7(47):77291-77305.
[cited by applicant]
Dodonova et al., “Synthesis of 4-aryl-, 2, 4-diaryl-and 2, 4, 7-triarylpyrrolo [2, 3-d] pyrimidines by a combination of the Suzuki cross-coupling and N-arylation reactions,” Tetrahedron, 2012, 68(1):329-339.
[cited by applicant]
Dorai, “Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function,” Hybridoma., Apr. 1991, 10(2):211-217.
[cited by applicant]
Dufies et al., “Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells,” Oncotarget, Nov. 2011, 2(11):874-885.
[cited by applicant]
Ecuador Opposition in Ecuador Application No. SENADI-2020-21655, dated May 5, 2021, 27 pages.
[cited by applicant]
Eurasian Office Action in Eurasian Application No. 201892188, dated Oct. 21, 2019, 6 pages.
[cited by applicant]
Eurasian Office Action in Eurasian Application No. 202190153, dated Jul. 14, 2022, 8 pages.
[cited by applicant]
European Extended Search Report in European Application No. 21196789.8, dated Feb. 15, 2022, 7 pages.
[cited by applicant]
European Office Action in European Application No. 17715620.5 dated Sep. 24, 2020, 4 pages.
[cited by applicant]
Feneyrolles et al., “Axl kinase as a key target for oncology: focus on small molecule inhibitors,” Mol Cancer Therapy, Sep. 2014, 13(9): 2141-8.
[cited by applicant]
Freshney et al., “Culture of Animal Cells,” A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
[cited by applicant]
Friend, “Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection,” Transplantation, 1999, 68:1632-1637.
[cited by applicant]
Gao et al., “High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response,” Nat Med., 2015, 21:1318-1325.
[cited by applicant]
Genbank Accession No. NP_005009 “programmed cell death protein 1 precursor [
[cited by applicant]
Ghosh, “Synthesis of 4-oxazolinephenylboronic acid and heterobiaryl oxazolines via a Suzuki reaction,” Journal of Chemical Research, Apr. 2009, 4:205-207.
[cited by applicant]
Gibson et al., “Pharmaceutical Preformulation and Formulation,” CRC Press LLC: Boca Raton, Fla., 2009, 2nd Edition, 559 pages.
[cited by applicant]
Golub et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,” Science, 1999, 286: 531-537.
[cited by applicant]
Gould, “Salt Selection for Basic Drugs,” Int J Therapeutics, 1986, 33:201-217.
[cited by applicant]
Graddis et al., “Designing proteins that work using recombinant technologies,” Curr Pharm Biotechnol., 2002, 3:285-297.
[cited by applicant]
Graham et al., “Cloning and developmental expression analysis of the murine c-mer tyrosine kinase,” Oncogene, Jun. 1995, 10(12): 2349-59.
[cited by applicant]
Graham et al., “Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia,” Clinical Cancer Research, May 1, 2006 12(9):2662-2669.
[cited by applicant]
Graham et al., “The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer,” Nat. Rev. Cancer, Dec. 2014, 14(12): 769-85.
[cited by applicant]
Guo et al., “Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models”, Oncotarget, Oct. 27, 2017, 8(52):89761-89774.
[cited by applicant]
Gustafsson et al., “Differential expression of Axl and Gas6 in renal cell carinoma reflecting tumor advancement and survival,” Clin. Cancer Res., 2009, 15: 4742-4749.
[cited by applicant]
Hand et al., “Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant,” Cancer Immunol Immunother., 1992, 35(3):165-174.
[cited by applicant]
Harmsen et al., “Properties, production, and applications of camelid single-domain antibody fragments,” Appl Microbiol Biotechnol., 2007, 77(1):13-22.
[cited by applicant]
Hobbs et al., “Interaction of aglycosyl immunoglobulins with the IgG Fc transport receptor from neonatal rat gut: comparison of deglycosylation by tunicamycin treatment and genetic engineering,” Mol Immunol., 1992, 29:9…
[cited by applicant]
Holland et al., “R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer,” Cancer Research, Feb. 2010, 70(4): 1544-1554.
[cited by applicant]
Holliger et al., “‘Diabodies’: small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci USA., 1993, 90:6444-6448.
[cited by applicant]
Hsieh et al., “The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma,” Oncotarget, Jun. 14, 2016, 7(24):36956-36970.
[cited by applicant]
Huang et al., “Structural insights into the inhibited states of the Mer receptor tyrosine kinase,” Journal of Structural Biology, 2009, 165: 88-96.
[cited by applicant]
Hudson, et al., “High avidity scFv multimers; diabodies and triabodies,” J Immunol Methods., 1999, 231:177-189.
[cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Hutterer et al., “Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme,” Clinical Cancer Research, Jan. 1, 2008, 14(1):1…
[cited by applicant]
Indian Office Action in Indian Application No. 201817040446, dated Aug. 18, 2021, 7 pages.
[cited by applicant]
Indian Office Action in Indian Application No. 202017016215, dated Oct. 4, 2021, 7 pages.
[cited by applicant]
Indian Office Action in Indian Application No. 202117003850, dated Jun. 20, 2022, 5 pages.
[cited by applicant]
Indonesian Office Action in Indonesian Application No. P00202002890, dated Dec. 2, 2021, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2016/048716, dated Nov. 2, 2016, 12 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2017/024270, dated Oct. 2, 2018, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/052925, dated Mar. 31, 2020, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2019/039825, dated Jan. 7, 2021, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2021/021053, dated Sep. 15, 2022, 8 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/031625, dated Jul. 7, 2016, 11 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/046574, dated Oct. 21, 2016, 14 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/048716, dated Nov. 2, 2016, 12 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2017/024270, dated Jun. 14, 2017, 18 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2018/052925, dated Nov. 5, 2018, 14 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2019/039825, dated Nov. 11, 2019, 14 pages.
[cited by applicant]
International Search Report in Written Opinion in International Application No. PT/US2021/021053, dated Jun. 16, 2021, 16 pages.
[cited by applicant]
Isaacs et al., “Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential,” J Immunol., May 1992, 148(10):3062-3071.
[cited by applicant]
Israeli Office Action in Israeli Application No. 261,957, dated Oct. 28, 2020, 10 pages.
[cited by applicant]
Israeli Office Action in Israeli Application No. 273579, dated Apr. 25, 2022, 4 pages.
[cited by applicant]
Izumchenko et al. “Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors,” Ann Oncol., 2017, 28:2595-605.
[cited by applicant]
Japanese Office Action in Japanese Application No. 2018-550711, dated Mar. 9, 2021, 5 pages.
[cited by applicant]
Jin et al., “Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review,” Clin Transl Oncol., Jul. 2010, 12:473-480.
[cited by applicant]
Johnson et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials,” British J. of Cancer., May 18, 2001, 84(10):1424-1431.
[cited by applicant]
Kaufman and Sharp, “Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary dna gene,” Mol Biol., 1982, 159:601-621.
[cited by applicant]
Keegan et al., “Preclinical Evaluation of AMG 925, a FLT3/CDK4 Kinase Inhibitor for Treating Acute Myeloid Leukemia,” Molecular Cancer Therapeutics, Apr. 2014, 13(4): 880-889.
[cited by applicant]
Kerekes et al., “Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure,” J. Med. Chem., 2011, 54: 201-210.
[cited by applicant]
Klimke and Ludemann, “Further evidence for a S-syn correlation in the purine (ß) ribosides: the solution conformation of two tricyclic analogs of adenosine and guanosine,” Journal of Biosciences, 1979, 34C(9-10): 653-7.
[cited by applicant]
Koorstra et al., “The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new threapeutic target,” Cancer Biol. Ther., Apr. 2009, 8(7): 618-626.
[cited by applicant]
Korean Office Action in Korean Application No. 10-2018-7031294, dated Oct. 27, 2021, 16 pages.
[cited by applicant]
Lai and Lemke, “An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system,” Neuron, May 1991, 6(5): 691-704.
[cited by applicant]
Lamoyi, E., “Preparation of F(ab')2 fragments from mouse IgG of various subclasses,” Methods in Enzymology, 1989, 121:652-663.
[cited by applicant]
Leatherbarrow and Dwek, “The effect of aglycosylation on the binding of mouse IgG to staphylococcal protein A,” FEBS Letters., 1983, 164(2):227-230.
[cited by applicant]
Leatherbarrow et al., “Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor,” Mol Immunol., 1985, 22(4):407-415.
[cited by applicant]
Lee-Sherick et al., “Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia,” Oncogene, Nov. 2013, 32(46):5359-5368.
[cited by applicant]
Lei et al., “Characterization of the Erwinia carotovora pelB gene and its product pectate lyase,” J Bacteriol., 1987, 169(9):4379-4383.
[cited by applicant]
Lemke, “Biology of the TAM Receptors,” Cold Spring Harb Perspect Biol., 2013, 5: 1-17.
[cited by applicant]
Lew et al., “Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities,” Elife, Sep. 2014, 3:e03385.
[cited by applicant]
Li et al., “Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis,” Oncogene, Oct. 2009, 28(39): 3442-55.
[cited by applicant]
Li et al., “Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3,” Journal of Medicinal Chemistry, 2014, 57(8): 3430-3449.
[cited by applicant]
Linger et al., “Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer,” Oncogene, Jul. 2013, 32(29): 3420-3431.
[cited by applicant]
Linger et al., “Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors,” Expert Opin. Ther. Targets, Oct. 2010, 14(10): 1073-1090.
[cited by applicant]
Linger et al., “TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer,” Adv. Cancer Research, 2008, 100: 35-83.
[cited by applicant]
Lippincott Williams & Wilkins, “Remington: The Science and Practice of Pharmacy,” 2005, 21st ed., 1 page, Title page.
[cited by applicant]
Liu et al., “Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma,” PLOS One, May 16, 2016, 1-13.
[cited by applicant]
Liu et al., “Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia,” Supporting Information, ACS Med. Chem. Lett., 2012, 53 pages.
[cited by applicant]
Liu et al., “Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia,” ACS Med. Chem. Lett., 2012, 3(2): 129-134.
[cited by applicant]
Liu et al., “Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma,” Blood, Jul. 15, 2010, 116(2):297-305.
[cited by applicant]
Liu et al., “UNC1062, a new and potent Mer inhibitor,” European Journal of Medicinal Chemistry, 2013, 65: 83-93.
[cited by applicant]
Lu and Lemke, “Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family,” Science, Jul. 2001, 293(5528): 306-11.
[cited by applicant]
Lu et al, “The Effect of a Point Mutation on the Stability of IgG4 as Monitored by Analytical Ultracentrifugation,” J. Pharmaceutical Sciences, 2008, 97:960-969.
[cited by applicant]
Ludwig, et al., “Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer,” Cancer Research, Jan. 1, 2018, 78(1):246-255.
[cited by applicant]
Mao et al., “Quantitation of poloxamers in pharmaceutical formulations using size exclusion chromatography and colorimetric methods,” Journal of Pharmaceutical and Biomedical Analysis, 2004, 35: 1127-1142.
[cited by applicant]
Mexican Office Action in Mexican Application No. MX/a/2018/011792, dated Jul. 11, 2022, 5 pages.
[cited by applicant]
Millstein et al., “Hybrid hybridomas and their use in immunohistochemistry,” Nature, 1983, 305:537-539.
[cited by applicant]
Mizushima et al., “pEF-BOS, a powerful mammalian expression vector,” Nucleic Acids Res., 1990, 18:5322.
[cited by applicant]
Mollard et al., “Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors,” ACS Medicinal Chemistry Letters, 2011, 2: 907-912.
[cited by applicant]
Moller et al., “Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain,” J Biol Chem., Dec. 2010, 285(49):38348-38361.
[cited by applicant]
Morissette et al., “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids,” Advanced Drug Delivery Reviews, 2004, 56:257-300.
[cited by applicant]
Morris et al., “An Integrated Approach to the Selection of Optimal Salt Form for a New Drug Candidate,” Int J Pharm., 1994, 105:209-217.
[cited by applicant]
Morrison, “Transfectomas provide novel chimeric antibodies,” Science, 1985, 229:1202-1207.
[cited by applicant]
Mudduluru et al., “Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer,” Mol. Cancer Res., Feb. 2010, 8(2): 159-169.
[cited by applicant]
Mulligan et al., “Synthesis of rabbit beta-globin in cultured monkey kidney cells following infection with a SV40 beta-globin recombinant genome,” Nature, Jan. 1979, 277(5692):108-114.
[cited by applicant]
Myers et al., “AXL inhibitors in cancer: A medicinal chemistry perspective,” Journal of Medicinal Chemistry, 2015, pp. 1-53.
[cited by applicant]
Myers et al., “Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment,” Molecular Cancer, 2019, 18:94.
[cited by applicant]
Neau “Pharmaceutical Salts,” Water-Insoluble Drug Formulation, 2008, 417-435.
[cited by applicant]
Nishimura et al., “Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice,” Science, 2001, 291(5502): 319-22.
[cited by applicant]
Nose and Wigzell, “Biological significance of carbohydrate chains on monoclonal antibodies,” 1983, Proc Natl Acad Sci USA., Nov. 1983, 80(21):6632-6636.
[cited by applicant]
O'Bryan et al., “axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase,” Mol. Cell Biol., Oct. 1991, 11(10): 5016-31.
[cited by applicant]
Oi et al., “Chimeric antibodies,” BioTechniques, 1986, 4:214-221.
[cited by applicant]
Okamoto et al., “Oligonucleotides containing 7-vinyl-7-deazaguanine as a facile strategy for expanding the functional diversity of DNA,” Bioorganic & Medicinal Chemistry Letters, 2002, 12(15): 1895-1896.
[cited by applicant]
Paolino et al., “The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells,” Nature, 2014, 19 pages.
[cited by applicant]
Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,” Nat. Rev. Cancer, Mar. 2012, 12(4): 252-64.
[cited by applicant]
Philippine Office Action in Philippine Application No. 1/2018/502102, dated Jun. 23, 2022, 4 pages.
[cited by applicant]
Philippine Office Action in Philippine Application No. 1/2018/502102, dated Sep. 14, 2021, 5 pages.
[cited by applicant]
Philips et al., “Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies,” International Immunology, Oct. 2014, 27(1):39-46.
[cited by applicant]
Pluckthun, “Antibodies from
[cited by applicant]
Plueckthun and Skerra, “Expression of functional antibody Fv and Fab fragments in
[cited by applicant]
Powell et al., “Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase,” Bioorganic & Medicinal Chemistry Letters, 2013, 23: 1046-1050.
[cited by applicant]
Powell et al., “Novel and selective spiroindoline-based inhibitors of sky kinase,” Bioorganic & Medicinal Chemistry Letters, 2012, 22: 190-193.
[cited by applicant]
Powers et al., “Expression of single-chain Fv-Fc fusions in Pichia pastoris,” J Immunol Methods., 2001, 251:123-135.
[cited by applicant]
Raju, “Glycosylation Variations with Expression Systems and Their Impact on Biological Activity of Therapeutic Immunoglobulins,” BioProcess International, Apr. 2003, 44-53.
[cited by applicant]
Rankin et al., “AXL is an essential factor and therapeutic target for metastatic ovarian cancer,” Cancer Research, Oct. 1, 2010, 70(19), 7570-7579.
[cited by applicant]
Rao et al., “Preliminary results of a Phase 2 study of INCMGA00012 in patients with squamous carcinoma of the anal canal (SCAC) who have progressed following platinum-based chemotherapy (NCT03597295,” J Immunother of Ca…
[cited by applicant]
Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418.
[cited by applicant]
Rho et al., “MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation,” AARC Journals, 2013, 253-262.
[cited by applicant]
Rios-Doria et al., “A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity”, Front in Oncol., Dec. 7, 2020, 10:598477.
[cited by applicant]
Rousseaux, J. et al., “Optimal conditions for the preparation of proteolytic fragments from monoclonal IgG of different rat IgG subclasses,” Methods in Enzymology, 1989, 121:663-669.
[cited by applicant]
Rowe et al., “Handbook of Pharmaceutical Excipients,” The Pharmaceutical Press and the American Pharmaceutical Association, 2009, 6th edition, 917 pages.
[cited by applicant]
Sausville et al., “Contributions of human tumor xenografts to anticancer drug development,” Cancer Research, Apr. 1, 2006, 66(7):3351-3354.
[cited by applicant]
Schlegel et al., “MERTK receptor tyrosine kinase is a therapeutic target in melanoma,” The Journal of Clinical Investigation, May 2013, 123(5): 2257-2267.
[cited by applicant]
Schroeder et al., “Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of th…
[cited by applicant]
Shibata et al., “Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma,” The Journal of Immunology, 2014, 192: 3569-3581.
[cited by applicant]
Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem., 2001,…
[cited by applicant]
Shields et al., “Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity,” J Biol Chem., 2002, 277(30):26733-26740.
[cited by applicant]
Shinkawa et al., “The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cyt…
[cited by applicant]
Singer et al., “Photochromism of Diarylethene-Functionalized 7-Deazaguanosines,” European Journal of Organic Chemistry, 2013, 14: 2766-2769.
[cited by applicant]
Skardziute, “Optical study of the formation of pyrrolo[2,3-d]pyrimidine-based fluorescent nanoaggregates,” Tetrahedron, 2013, 69(46):9566-9572.
[cited by applicant]
Storey et al., “Solid State Characterization of Pharmaceuticals,” 2011, 170 pages.
[cited by applicant]
Strassmaier and Karpen, “Novel N7- and N1-Substituted cGMP Derivatives Are Potent Activators of Cyclic Nucleotide-Gated Channels,” Journal of Medicinal Chemistry, Aug. 2007, 50: 4186-4194.
[cited by applicant]
Suarez et al., “Inhibitors of the TAM subfamily of tyrosine kinsases: Synthesis and biological evaluation,” European Journal of Medicinal Chemistry, 2013, 61: 2-25.
[cited by applicant]
Swarbrick et al., “Salt Forms of Drugs and Absorption,” Encyclopedia of Pharmaceutical Technology, 1996, 13:453-499.
[cited by applicant]
Tai et al., “Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1,” Oncogene, Jul. 2008, 27(29): 4044-55.
[cited by applicant]
Tao et al., “Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region,” J Immunol., Oct. 15, 1989, 143(8):2595-2601 (Abstr…
[cited by applicant]
Tempest et al., “Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo,” Biotechnology, 1991, 9:266-271.
[cited by applicant]
Tomlinson et al., “The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops” J Mol Biol., 1992, 227(3):776-798.
[cited by applicant]
Tomlinson et al., “The structural repertoire of the human V kappa domain,” EMBO J., 1995, 14:4628-4638.
[cited by applicant]
Traore et al., “New aminopyrimidine derivatives as inhibitors of the TAM family,” European Journal of Medicinal Chemistry, 2013, 70: 789-801.
[cited by applicant]
Tumkevicius, “Pyrrolo [2, 3-d] pyrimidine-Core-Extended x-Systems: Synthesisof 2, 4, 7-Triarylpyrrolo [2, 3-d] pyrimidines,” Synlett, 2011, 12:1705-1708.
[cited by applicant]
Tumkevicius, “Synthesis and photophysical properties of oligoarylenes with a pyrrolo [2, 3-d] pyrimidine core,” Tetrahedron Letters (2010), 51(30), 3902-3906.
[cited by applicant]
Ukraine Office Action in Ukraine Application No. a201810566, dated Dec. 15, 2020, 8 pages.
[cited by applicant]
Ukraine Office Action in Ukraine Application No. a202002558, dated Feb. 18, 2022, 8 pages.
[cited by applicant]
Umana et al., “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity,” Nat Biotechnol., Feb. 1999, 17(2):176-180.
[cited by applicant]
Urbonas et al., “A Novel Highly Site-Selective Synthesis of 2,4,7-Triarylpyrrolo[2,3-d]pyrimidines by a Combination of Palladium(0)-, Nickel(0)-, and Copper(I)-Catalyzed Cross-Coupling Reactions,” Synlett, 2013, 24(11):…
[cited by applicant]
Urlaub and Chasin, “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” Proc Natl Acad Sci USA., 1980, 77:4216-4220.
[cited by applicant]
Waizeneggar et al., “Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma,” Leukemia, 2015, 29: 696-704.
[cited by applicant]
Walker et al., “Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors,” Biochem J., 1989, 259:347-353.
[cited by applicant]
Wang et al., “Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme,” Oncogene, Feb. 2013, 32(7): 872-882.
[cited by applicant]
Ward and Ghetie, “The effector functions of immunoglobulins: implications for therapy,” Therapeutic Immunology, 1995, 2:77-94.
[cited by applicant]
Cited By (1)